About Us

Learn more about Vitalcoin

A unique opportunity for contributors to benefit from the delivery of revolutionary new medical solutions. This process will result in a paradigm shift within the health services industry and will have a significant impact on the longevity and quality of life for existing and future generations. This is being achieved by diagnosing neurodegenerative and life threatening, as well as majorly life influencing diseases like Alzheimer’s, Parkinson’s, Huntington’s, Motor neuron and Cancer at an early stage and treating those with simplistic influenza like treatments with more predictable results and without side effects. In addition the R&D team invented a method by which the structural information of any molecule (e.g. drug) can be transferred into a living tissue by means of non-invasive procedures. The team also devised subscription based monthly recurring services to collect bio-genetically important data, with the benefit of detecting and investigating significant disparities in chronological vs biological age.

The project is a cooperation between the companies Digital Media Communications & Technology Fund, MyProducts Kft and the department of genetics of the largest University in Hungary (ELTE).

The MyProducts team developed the bitcoin forked crypto currency as a utility coin in which all of the mentioned services will be denoted in, which via people can save an anonymously transferrable asset for their future.

We are initially targeting Europe, but incrementally shortly after the entire world by operating health centers or exclusively licensing the services to third parties in each country.

Aging is driven by the lifelong, progressive accumulation of cellular damage, which leads to the development of an age-associated degenerative disease (e.g. cancer, a neurodegenerative pathology, diabetes, fibrosis and atrophy), and, ultimately, to death. Such damages mainly include oxidized, aggregated and misfolded (i.e. ineffective) proteins that interfere with cellular processes, thereby causing the senescence and subsequent loss of the affected cell. Massive levels of cell death then result in the incidence of a fatal degenerative disease. Despite its medical, social and economic significance, understanding the primary molecular (genetic) mechanisms leading to cellular damage remains unresolved (this issue actually represents one of the greatest challenges in science). This problem is nicely reflected by the following statement: “Some aspects of ageing remain particularly enigmatic. One of these is the all-important question of what actually causes ageing.” Cynthia Kenyon. The genetics of ageing. Nature 464:504–512, 2010).

Our scientific team has explored the primary genetic mechanism of the aging process. Accordingly, aging is primarily caused by the mutagenic activity of mobile genetic elements (MGEs; also called “jumping genes”), which, when mobilized, can disrupt functional – coding and regulatory – DNA sequences. The functional significance of MGEs is reflected by the fact that they constitute nearly half of the human genome. The progressive activation of MGEs during the adult lifespan leads to a significant level of genomic instability at advanced ages, which is a hallmark of the aging process.

Relevant publications:

• Highly efficient RNAi and Cas9-based auto-cloning systems for C. elegans research

  Sturm Á, Saskoi É, Kovács T, Weinhardt N, Vellai T.

  Nucleic Acids Res. 2018 Jun 19. doi: 10.1093/nar/gky516. [Epub ahead of print]

  PMID:29924347

• Prediction and characterization of human ageing-related proteins by using machine learning.

  Kerepesi C, Daróczy B, Sturm Á, Vellai T, Benczúr A.

  Sci Rep. 2018 Mar 6;8(1):4094. doi: 10.1038/s41598-018-22240-w.

  PMID:29511309

• The Piwi-piRNA pathway: road to immortality.

  Sturm Á, Perczel A, Ivics Z, Vellai T.

  Aging Cell. 2017 Oct;16(5):906-911. doi: 10.1111/acel.12630. Epub 2017 Jun 27.

  PMID:28653810

• The mechanism of ageing: primary role of transposable elements in genome disintegration.

  Sturm Á, Ivics Z, Vellai T.

  Cell Mol Life Sci. 2015 May;72(10):1839-47. doi: 10.1007/s00018-015-1896-0. Epub 2015 Apr 3.

  PMID:25837999

Based on these achievements, we are establishing the following:

• New generation drug candidates with potent antitumorigenic effects. By using these interventions, cancer is a treatable (influenza-like) disease. We are triggering the aging process in otherwise non-aging cancer cells (these cells display replicative immortality).
• Diagnostic tool for determining the biological age of an individual (age determination from DNA sample). At advanced ages, the biological age often differs from the chronological age (the number of years one lives). Hence, this intervention is capable of uncovering neurodegenerative processes at early stages when such a disease is not yet manifested phenotypically, and can be treated effectively.
• New generation drug candidates with potent neuroprotective effects to prevent or treat neurodegenerative pathologies.
• Antiaging pharmacological interventions.
• Home-performed DNA diagnostic tools, by which anyone can detect the presence of a pathogenic agent or a disease-associated gene variant.
• New generation (auto) cloning system, by which any DNA fragment can be cloned without using enzymes.

These developments will be administrated and followed in a closed, real-time system, and investors will get insight into this information. Thus, they can follow the stages of inventions achieved by us. They will also get rights of first refusal to take advantage of all of our inventions.